RGC
REGN icon

Roberts, Glore & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Roberts, Glore & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-280
Closed -$216K – 252
2026
Q1 		$216K Sell
280
-8
-3% -$6.13K 0.06% 206
2025
Q4 		$222K Buy
+288
New +$196K 0.06% 207

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Roberts, Glore & Co's REGN Position: Q2 2026 in Review

Roberts, Glore & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 280 shares — an estimated $216K sold.

Roberts, Glore & Co first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $222K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Roberts, Glore & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Roberts, Glore & Co sold 280 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $216K.
  • Roberts, Glore & Co first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Roberts, Glore & Co's Regeneron Pharmaceuticals position peaked at $222K in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Roberts, Glore & Co's 13F filing for Q2 2026, filed 11 Aug 2026.